Overview

Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor

Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
Human coagulation factor VII is a vitamin K-dependent serine endogenous protease, and its activated form plays an important role in the coagulation process. Recombinant human activated coagulation factor VII is an activated state coagulation factor VII obtained by recombinant means.
Phase:
Phase 3
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.